AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31164115 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on initial weight loss, cancer type, appetite, and chronic obstructive pulmonary disease as predictors.
Number of subjects: 628
Study 31164115 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-level 1 patients (WL < 3%, breast or hematologic cancer, no or little appetite loss)
Number of subjects: 628
Study 31164115 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-level 5 patients (WL 3-5%)
Number of subjects: 628
Study 31164172 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy (CIRT)
Number of subjects: 64
Study 31164347 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma samples analyzed by LC/MS from incident breast cancer cases.
Number of subjects: 422
Study 31164347 — intervention group
Group type: COMPARATOR
Intervention: Matched controls from the SU.VI.MAX cohort.
Number of subjects: 422
Study 31164394 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed by 400 μg sublingual misoprostol every 3 hours until expulsion
Number of subjects: 306
Study 31164456 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1118 (5.0 mg/kg)
Number of subjects: 63
Study 31164456 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1118 (4.0 mg/kg)
Number of subjects: 63
Study 31164456 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1118 in Cohort 1 (CRC without prior anti-EGFR treatment)
Number of subjects: 63
Study 31164456 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1118 in Cohort 2 (CRC with tumors resistant to anti-EGFR therapy)
Number of subjects: 63
Study 31164456 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1118 in Cohort 3 (EGFR-overexpressing gastric cancer)
Number of subjects: 63
Study 31164926 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (titrated from 0.6 mg q.d. to 1.8 mg q.d. over 4 weeks)
Number of subjects: 0
Study 31164926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31164926 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (titrated from 500 mg b.i.d to 1000 mg b.i.d. over 4 weeks)
Number of subjects: 0
Study 31164990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW) online behavioral intervention
Number of subjects: 30
Study 31164990 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 30
Study 31165541 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole breast once-weekly hypofractionated radiotherapy (wHF-RT) to a total dose of 30 Gy, in 5 fractions of 6 Gy
Number of subjects: 44
Study 31165630 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH-N participants
Number of subjects: 0
Study 31165630 — intervention group
Group type: COMPARATOR
Intervention: Notified partners
Number of subjects: 0
Study 31165630 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants overall
Number of subjects: 0
Study 31165630 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 31165670 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche categorized (≤10, 11, 12, 13, 14, ≥15 years) with age 12 as reference
Number of subjects: 648
Study 31165709 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Up smartphone app
Number of subjects: 142
Study 31165709 — intervention group
Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 142
Study 31166442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 1 month
Number of subjects: 9
Study 31166554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoabdominoplasty
Number of subjects: 20
Study 31166567 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography for diagnosis of advanced liver fibrosis
Number of subjects: 400
Study 31166567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical factors evaluated
Number of subjects: 400
Study 31166701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge-enhanced ACL repair (BEAR)
Number of subjects: 20
Study 31166701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring autograft
Number of subjects: 20
Study 31166701 — intervention group
Group type: COMPARATOR
Intervention: Contralateral intact ACLs
Number of subjects: 20
Study 31166857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial fluorescence imaging in combination with clinical evaluation of signs and symptoms (CSS)
Number of subjects: 19
Study 31166857 — intervention group
Group type: COMPARATOR
Intervention: Clinical evaluation of signs and symptoms (CSS) alone
Number of subjects: 19
Study 31167051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (5.6 years of treatment)
Number of subjects: 1655
Study 31167051 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 1655
Study 31167060 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide treatment
Number of subjects: 0
Study 31167060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no macrolide treatment)
Number of subjects: 0
Study 31167654 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide (0.5 and 1.0 mg)
Number of subjects: 3297
Study 31167654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3297
Study 31167654 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 3297
Study 31167802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral idasanutlin
Number of subjects: 0
Study 31167890 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pregestational type 1 diabetes
Number of subjects: 0
Study 31167890 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy BMI
Number of subjects: 0
Study 31167890 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring metabolic risk factors
Number of subjects: 0
Study 31167890 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring level of sCD163
Number of subjects: 0
Study 31167965 — intervention group
Group type: EXPERIMENTAL
Intervention: COL7A1-modified autologous fibroblasts (3 intradermal injections of ~1 × 10^6 cells/cm2)
Number of subjects: 4
Study 31167965 — intervention group
Group type: EXPERIMENTAL
Intervention: COL7A1-modified autologous fibroblasts
Number of subjects: 4
Study 31168327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin concentration increase of 1 µg/mL
Number of subjects: 197
Study 31168327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin concentration > median (2.8 ± 4.8 vs 4.2 ± 5.7)
Number of subjects: 197
Study 31168381 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency percutaneous coronary intervention (PCI)
Number of subjects: 324
Study 31168384 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn measurements at 0 hour/30 min algorithm
Number of subjects: 1000
Study 31168384 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn measurements at 0 hour/1 hour algorithm
Number of subjects: 1000
Study 31168384 — intervention group
Group type: COMPARATOR
Intervention: hs-cTn measurements at 0 hour/3 hour algorithm
Number of subjects: 1000
Study 31168392 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 25
Study 31168392 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminus pro-brain natriuretic peptide (NT-proBNP)
Number of subjects: 25
Study 31168392 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin-T (hs-TnT)
Number of subjects: 25
Study 31168392 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin-I (hs-TnI)
Number of subjects: 25
Study 31168392 — intervention group
Group type: EXPERIMENTAL
Intervention: ST2
Number of subjects: 25
Study 31168494 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide
Number of subjects: 37
Study 31168494 — intervention group
Group type: COMPARATOR
Intervention: Any other approved antiseizure drug (ASD)
Number of subjects: 37
Study 31168885 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986231 (HNO donor)
Number of subjects: 0
Study 31168885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31169386 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported cognitive difficulties
Number of subjects: 236
Study 31169386 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fatigue, pain, and depression levels
Number of subjects: 236
Study 31169386 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective neuropsychological tests (Stroop I-IV, CVLT-II, WAIS-III, PASAT)
Number of subjects: 236
Study 31169831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 5072
Study 31170515 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring for low-risk disease
Number of subjects: 2664
Study 31170515 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical treatment options for higher risk prostate cancer
Number of subjects: 2664
Study 31170515 — intervention group
Group type: COMPARATOR
Intervention: Random allocation
Number of subjects: 2664
Study 31170515 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preferences
Number of subjects: 2664
Study 31170847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine, carboplatin, and dexamethasone (BCD)
Number of subjects: 85
Study 31170941 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF) initiative including daily free healthy lunches and structured physical activity sessions
Number of subjects: 4
Study 31170941 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF) initiative
Number of subjects: 4
Study 31170954 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 12
Study 31171444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant dabrafenib plus trametinib
Number of subjects: 35
Study 31171638 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion dose density
Number of subjects: 1267
Study 31171638 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1267
Study 31171735 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus Crizotinib (starting doses: axitinib 3 mg plus crizotinib 200 mg)
Number of subjects: 0
Study 31171735 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus Crizotinib
Number of subjects: 0
Study 31171916 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching: Individual (nursing intervention)
Number of subjects: 200
Study 31171916 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200
Study 31171975 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused community health worker (CHW)-delivered lifestyle intervention
Number of subjects: 0
Study 31172178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein (2%) overfeeding for 6 weeks
Number of subjects: 7
Study 31172178 — intervention group
Group type: COMPARATOR
Intervention: 24-h fasting
Number of subjects: 7
Study 31172178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein overfeeding
Number of subjects: 7
Study 31172178 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased 24EE above requirements for achieved body size post-overfeeding
Number of subjects: 7
Study 31172178 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 24EE during 200% normal-protein overfeeding
Number of subjects: 7
Study 31172178 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum FGF21 concentrations during overfeeding
Number of subjects: 7
Study 31172977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus boosted-darunavir dual therapy
Number of subjects: 51
Study 31173649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine in young children
Number of subjects: 93
Study 31174053 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II
Number of subjects: 652
Study 31174053 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-related procedures post-LVAD
Number of subjects: 652
Study 31174053 — intervention group
Group type: COMPARATOR
Intervention: LVAD infections
Number of subjects: 652
Study 31174106 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA/LAMA therapy
Number of subjects: 0
Study 31174106 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oxygen therapy
Number of subjects: 0
Study 31174106 — intervention group
Group type: EXPERIMENTAL
Intervention: Three COPD exacerbations during follow-up
Number of subjects: 0
Study 31174106 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA or ICS/LABA/LAMA associated therapy
Number of subjects: 0
Study 31174106 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT questionnaire score
Number of subjects: 0
Study 31174106 — intervention group
Group type: COMPARATOR
Intervention: Hospitals managed by local healthcare authorities
Number of subjects: 0
Study 31175126 — intervention group
Group type: EXPERIMENTAL
Intervention: Research without prior consent (RWPC)
Number of subjects: 20
Study 31175126 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent discussions with the research team
Number of subjects: 20
Study 31175126 — intervention group
Group type: EXPERIMENTAL
Intervention: RWPC approach
Number of subjects: 20
Study 31175126 — intervention group
Group type: EXPERIMENTAL
Intervention: Future diagnostic studies
Number of subjects: 20
Study 31175167 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for 3 weeks per 4-week cycle
Number of subjects: 59
Study 31175167 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 59
Study 31175375 — intervention group
Group type: EXPERIMENTAL
Intervention: Revive SE stent retriever
Number of subjects: 100
Study 31175500 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 250
Study 31175500 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography and Integrated Pulmonary Index™ algorithm (IPI)
Number of subjects: 250
Study 31175500 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 250
Study 31176355 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study 31176752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 85
Study 31177537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (SAHA), cladribine 5 mg/m², and rituximab (SCR)
Number of subjects: 0
Study 31177537 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31177556 — intervention group
Group type: EXPERIMENTAL
Intervention: C9orf72 hexanucleotide expansion carriers
Number of subjects: 72
Study 31177556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spinal cord imaging
Number of subjects: 72
Study 31177821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantom sirolimus-eluting bioresorbable scaffold
Number of subjects: 240
Study 31177991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injections of LTX-315 (oncolytic peptide)
Number of subjects: 1
Study 31178096 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA Monotherapy
Number of subjects: 47
Study 31178096 — intervention group
Group type: COMPARATOR
Intervention: Ineffective antidepressant medication taper
Number of subjects: 47
Study 31178096 — intervention group
Group type: COMPARATOR
Intervention: Medication-free period
Number of subjects: 47
Study 31178096 — intervention group
Group type: COMPARATOR
Intervention: Inclusion criteria adherence
Number of subjects: 47
Study 31178096 — intervention group
Group type: COMPARATOR
Intervention: Follow-up adherence
Number of subjects: 47
Study 31178349 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA ligase activity in PBMCs of patients with stable angina (SA)
Number of subjects: 124
Study 31178349 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA ligase activity in PBMCs of patients with non-ST elevation myocardial infarction (NSTEMI)
Number of subjects: 124
Study 31178349 — intervention group
Group type: COMPARATOR
Intervention: DNA ligase activity in PBMCs of controls
Number of subjects: 124
Study 31178349 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of DDR genes in patients with stable angina (SA)
Number of subjects: 124
Study 31178349 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of DDR genes in patients with non-ST elevation myocardial infarction (NSTEMI)
Number of subjects: 124
Study 31178998 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive phone telesystem
Number of subjects: 256
Study 31179027 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural interventions
Number of subjects: 458
Study 31179027 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 458
Study 31179061 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative acute lung injury (ALI)
Number of subjects: 53
Study 31179061 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation and fibrinolysis factors (PAI-1 in BALF and TF in serum and BALF)
Number of subjects: 53
Study 31179079 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating free tumor-derived DNA (ctDNA) from plasma
Number of subjects: 1311
Study 31179103 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers (metoprolol tartrate/metoprolol succinate/Bisoprolol Fumarate) within 24 hours of perioperative period
Number of subjects: 1309
Study 31179103 — intervention group
Group type: COMPARATOR
Intervention: Non-β-blockers
Number of subjects: 1309
Study 31179244 — intervention group
Group type: EXPERIMENTAL
Intervention: Trientine plus Carboplatin and Pegylated Liposomal Doxorubicin
Number of subjects: 0
Study 31179244 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31179386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 586
Study 31179386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) with loading dose
Number of subjects: 586
Study 31179499 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frequency and estimated amounts of sodium intake from salt added at the table (HP 2020 methodology)
Number of subjects: 450
Study 31179499 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured sodium intake from duplicate salt samples collected on recall days
Number of subjects: 450
Study 31179503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP)
Number of subjects: 0
Study 31179503 — intervention group
Group type: COMPARATOR
Intervention: Post-PrEP discontinuation
Number of subjects: 0
Study 31179781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous microwave ablation
Number of subjects: 0
Study 31180977 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use
Number of subjects: 193
Study 31180977 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid dosage
Number of subjects: 193
Study 31180977 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use/dosage
Number of subjects: 193
Study 31180994 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31181137 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx e-prescribing system
Number of subjects: 41
Study 31181137 — intervention group
Group type: COMPARATOR
Intervention: Usual recruitment practices
Number of subjects: 41
Study 31182031 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP3 levels below the 25th percentile
Number of subjects: 168
Study 31182031 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRP9 levels below the 25th percentile
Number of subjects: 168
Study 31182031 — intervention group
Group type: COMPARATOR
Intervention: CTRP3 and CTRP9 concentrations
Number of subjects: 168
Study 31182122 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 3 days (6 hours/day)
Number of subjects: 29
Study 31182122 — intervention group
Group type: COMPARATOR
Intervention: Electric trains (control)
Number of subjects: 29
Study 31182337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Hypoglycemia (FOH) assessed using the HFS-II questionnaire
Number of subjects: 298
Study 31182337 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with severe hypoglycemia in the previous 6 months
Number of subjects: 298
Study 31182337 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with higher HFS scores
Number of subjects: 298
Study 31182337 — intervention group
Group type: EXPERIMENTAL
Intervention: FOH as determined using the HFS-II questionnaire
Number of subjects: 298
Study 31182337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher FOH
Number of subjects: 298
Study 31182367 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid users
Number of subjects: 386
Study 31182367 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 386
Study 31182436 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 0
Study 31182436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 0
Study 31182488 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid intake (n-6 PUFAs)
Number of subjects: 214029
Study 31182488 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing saturated fatty acids with linoleic acid
Number of subjects: 214029
Study 31182525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Number of subjects: 0
Study 31182525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0
Study 31183189 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal endoscopic microscopy (CEM)
Number of subjects: 0
Study 31183189 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopic gastric mapping (white light endoscopy)
Number of subjects: 0
Study 31183463 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) protocol
Number of subjects: 0
Study 31183469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation practices; 98.0% of respondents practiced sedation; primary indication for sedation was mechanical ventilation (94.0%).
Number of subjects: 429
Study 31183469 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug choices for sedation; midazolam was the most preferred agent (90.0%).
Number of subjects: 429